• Telepsychiatry platform Cerebral has confirmed that it will stop prescriptions of controlled substances such as Xanax and Adderall to existing and new patients. Prescriptions will be halted on May 20 for new patients and October 15 for existing patients. The company has stated that it will continue to issue medications for opioid use disorder due to their limitations in accessibility.

<ul><li>Earlier this month, the company announced that it would stop writing new prescriptions for controlled medications that treat attention-deficit/hyperactivity disorder (ADHD) including Adderall and Ritalin, and it has now been extended to even existing patients. The company is also being sued by a former executive for its prescribing practices. It went on to announce a slew of new controls for its screening process including hiring additional practitioners, forming a review committee, and urine screening and surveys.</ul>

<ul><li>The company is already being investigated by the Drug Enforcement Agency (DEA) and recently the Department of Justice also launched an investigation into possible violations of the Controlled Substances Act.</ul>

• The firm’s investors are reportedly pushing to dismiss Founder and CEO Kyle Robertson after the decision to cease prescriptions according to Bloomberg. Cerebral is backed by investors such as SoftBank Vision Fund 2, Len Blavatnik’s Access Industries, and WestCap Group.